PT-141 Frequently Asked Questions

PT-141, also known as Bremelanotide, is a synthetic cyclic heptapeptide derived from Melanotan II. It acts as an agonist at melanocortin receptors MC3R and MC4R in the central nervous system. Unlike phosphodiesterase inhibitors, PT-141 works through a central nervous system mechanism rather than a vascular one. Peptides Pharma PT-141 is formulated at >99% purity in a lyophilized vial.

PT-141 activates melanocortin-3 and melanocortin-4 receptors (MC3R/MC4R) in the hypothalamus and limbic system. This central nervous system activation is thought to modulate sexual arousal through dopaminergic and oxytocinergic signalling pathways, rather than through peripheral vascular mechanisms. Studies indicate this distinct mechanism of action differentiates it from other compounds studied in sexual function research.

PT-141 is studied in research related to sexual function and arousal, melanocortin receptor pharmacology, neurobehavioural responses, appetite regulation, and central nervous system signalling. Its unique CNS-mediated mechanism makes it an important tool in neuroendocrine research.

Peptides Pharma PT-141 is manufactured to >99% purity in GMP-certified, ISO 7 cleanroom facilities. Each batch undergoes independent HPLC and mass spectrometry analysis. Certificates of Analysis confirming purity, identity, and sterility are provided for every batch.

Lyophilized PT-141 should be stored at -20°C for long-term storage or at 2-8°C for short-term use. Protect from light and moisture. Once reconstituted, store at 2-8°C and use within 28 days.

Add bacteriostatic water slowly down the inside wall of the vial to prevent damage to the peptide. Gently swirl until the lyophilized powder is fully dissolved — do not shake. The reconstitution volume should be selected based on the target concentration required for your research protocol.

Reconstituted PT-141 stored at 2-8°C with bacteriostatic water typically remains stable for up to 28 days. Use sterile technique when accessing the vial to maintain solution integrity and prevent microbial contamination.

Yes. Peptides Pharma PT-141 is supplied strictly for laboratory and research purposes. While Bremelanotide has received regulatory approval under certain brand names for specific clinical indications, Peptides Pharma's formulation is sold exclusively for research use and is not intended for self-administration.

PT-141 was developed from Melanotan II but has a distinct receptor selectivity profile. While Melanotan II activates MC1R through MC5R (producing pigmentation, appetite, and sexual function effects), PT-141 is more selective for MC3R and MC4R, focusing its activity on CNS-mediated effects without significant melanogenic activity at typical research concentrations.

PT-141 acts through a unique central nervous system mechanism that differs from most other peptide pathways. Combination studies should account for its melanocortin receptor activity and potential interactions with other neuroactive compounds. Researchers should consult published literature and design protocols based on peer-reviewed evidence.